Pay in 4 interest-free payments of $6.52 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Compared to tirzepatide, CagriSema offers strong appetite suppression with similar weight loss, adding another powerful option for obesity treatment
CagriSema vs Comparators Feature Receptor targets CagriSema Amylin/calcitonin + GLP-1 Tirzepatide (Zepbound) GIP + GLP-1 Semaglutide alone (Wegovy) GLP-1 Cagrilintide alone Amylin/calcitonin (DACRA) Feature Dosing frequency CagriSema Once weekly Tirzepatide (Zepbound) Once weekly Semaglutide alone (Wegovy) Once weekly Cagrilintide alone Once weekly Feature Maintenance dose CagriSema 2.4 mg + 2.4 mg Tirzepatide (Zepbound) Up to 15 mg Semaglutide alone (Wegovy) 2.4 mg Cagrilintide alone 2.4 mg (in REDEFINE arms) Feature Headline weight loss CagriSema 20.4% at 68 wks (REDEFINE 1, treatment-policy) Tirzepatide (Zepbound) Up to 22.5% at 72 wks (SURMOUNT-1, 15 mg arm) Semaglutide alone (Wegovy) 14.9% at 68 wks (REDEFINE 1 reference arm) Cagrilintide alone 11.5% at 68 wks (REDEFINE 1 reference arm) Feature FDA status (June 2026) CagriSema NDA filed Dec 2025
It is known as an anti-aging peptide due to its cellular repair and rejuvenation ability
Tell your healthcare provider if you have changes in vision during treatment with Wegovy
Enhances amino acid metabolism: Aids regulation of gluconeogenic and branched-chain amino acids, which are linked to metabolic health 2
US$ 20.78
US$ 21.74
US$ 24.35
